Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancer cases. Late diagnosis and failure of chemo- and radiotherapy are all too common, and many patients die soon after diagnosis. Here, we will make the case for the increased use of molecular imaging in PDAC preclinical research and in patient management
Pancreatic cancer is a leading cause of death from cancer but only a minority of patients with pancr...
Pancreatic ductal adenocarcinoma usually has a very poor outcome. The majority of patients present l...
textabstractDiscrimination of pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP)...
Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancrea...
International audienceEffective treatment for pancreatic cancer remains challenging, particularly th...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. To improve outcomes, there is a crit...
There is now compelling evidence to suggest that the molecular heterogeneity of histologically indis...
Pancreatic adenocarcinoma is one of the deadliest human malignancies. Early detection is difficult a...
For years, pancreatic cancer had a dismal prognosis with a long term survival of around 5%...
Background: Novel technology has enabled researchers to better characterize pancreatic cancers at th...
Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors, is a highly...
Pancreatic Ductal Adenocarcinoma (PDAC) constitutes a leading cause of cancer death globally. Its mo...
ABSTRACT: Development of novel imaging probes for cancer diagnostics remains critical for early dete...
Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates i...
Pancreatic cancer is a leading cause of death from cancer but only a minority of patients with pancr...
Pancreatic ductal adenocarcinoma usually has a very poor outcome. The majority of patients present l...
textabstractDiscrimination of pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP)...
Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancrea...
International audienceEffective treatment for pancreatic cancer remains challenging, particularly th...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. To improve outcomes, there is a crit...
There is now compelling evidence to suggest that the molecular heterogeneity of histologically indis...
Pancreatic adenocarcinoma is one of the deadliest human malignancies. Early detection is difficult a...
For years, pancreatic cancer had a dismal prognosis with a long term survival of around 5%...
Background: Novel technology has enabled researchers to better characterize pancreatic cancers at th...
Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors, is a highly...
Pancreatic Ductal Adenocarcinoma (PDAC) constitutes a leading cause of cancer death globally. Its mo...
ABSTRACT: Development of novel imaging probes for cancer diagnostics remains critical for early dete...
Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates i...
Pancreatic cancer is a leading cause of death from cancer but only a minority of patients with pancr...
Pancreatic ductal adenocarcinoma usually has a very poor outcome. The majority of patients present l...
textabstractDiscrimination of pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP)...